RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo trial offers hope for Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis study is testing a new drug called YL201, given alone with an immunotherapy drug or with an added chemotherapy, for people with advanced nasopharyngeal cancer that has returned or spread. The main goals are to find a safe dose and see how well the combinations work to contro…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Breakthrough combo therapy trial offers hope for Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis study is testing whether a new two-drug combination (MRG003 plus pucotenlimab) works better than standard chemotherapy for people with advanced nasopharyngeal cancer that has returned or spread. Researchers will enroll 446 patients whose cancer has worsened after at least on…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Tough-to-Treat head & neck cancer: trial tests four promising drug combos
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer (a type of head and neck cancer) that has come back or spread and has stopped responding to standard treatments, including immunotherapy. It aims to find out which of four different drug combinations is safest and most …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC